home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

The FDA Drug Development Process - Webinar by GlobalCompliancePanel

 
  December 18, 2013  
     
 


GlobalCompliancePanel, Online Training, 161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
2014-01-23


Overview: This web presentation will provide the attendee a comprehensive overview of the FDA Drug Development Process, IND/NDA applications and GCP, GLP and GMP regulations. 

Attendees will receive a foundation of knowledge about FDA's Drug Development Process, IND/NDA submission preparation, in-vitro studies, nonclinical studies and human clinical trials. Also discussed will be the underlying scientific and regulatory principles involved in the entire Drug Development Process. This web presentation will enable the attendee to prepare concise documents and provide FDA required information for fast product approval. 

Why Should You Attend: Professionals who require an understanding of the FDA Drug Development Process. Those professionals that require an understanding of what FDA requires relative to in-vitro, nonclinical and clinical studies. The necessary submissions required by FDA. An understanding of the entire FDA Drug Development Process is outlined for those who require this information. 

Areas Covered in the Session:
  • Understand the FDA Drug Development Process
  • Learn about INDs
  • Learn about NDAs
  • Learn the basics for in-vitro and nonclinical testing
  • Learn the basics about human clinical testing
  • Learn about FDA's IND/NDA review process

Who Will Benefit:
  • Regulatory Affairs Professionals
  • Quality Professionals
  • Clinical Professionals
  • Research Professionals
  • Manufacturing Professionals
  • Other professional that require an understanding of the FDA Drug Development Process
 
 
Organized by: GlobalCompliancePanel
Invited Speakers:
Albert A. Ghignone MS, RAC is the CEO of AAG Incorporated. For more than 30 years his focus has been on FDA related matters in regulatory affairs, quality assurance and clinical affairs. He has expertise in dealing with all aspects of the FDA approval process for drugs, biologics, medical devices and generic drugs. He has worked in every major segment of the industry-research, quality assurance, regulatory affairs, manufacturing and clinical. He has been responsible for regulatory submissions, registrations, FDA liaison, clinical studies, compliance activities and FDA training. He also has expertise in the assessment of product and facilities for due diligence relative to FDA requirements. He lectures throughout the world on numerous FDA related matters. 
 
 
Deadline for Abstracts: 2014-01-23
 
Registration:
Contact Information:
NetZealous LLC,
DBA GlobalCompliancePanel 
161 Mission Falls Lane,
Suite 216, Fremont, CA 94539, USA          
USA Phone:800-447-9407
Fax: 302-288-6884
webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com

Event Link - http://
bit.ly/1fj1XOq
E-mail: globalcompliancepanel@gmail.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.